Key result
SGLT2 inhibitors linked to ~33% lower bleeding risk in anticoagulated patients with AF.
Why the study?
Emerging evidence suggested that SGLT2 inhibitors may reduce arrhythmias and related complications in atrial fibrillation patients, but their impact on AF-associated adverse outcomes was unclear.
Does SGLT2i use reduce bleeding, hospitalizations, and arrhythmias in anticoagulated patients with atrial fibrillation?
Observational (n=102,640)
Yes
Does SGLT2i use reduce bleeding, hospitalizations, and arrhythmias in anticoagulated patients with atrial fibrillation?
In a large real-world cohort of anticoagulated patients with atrial fibrillation, SGLT2i use was associated with significantly lower risks of bleeding, AF-related hospitalizations, arrhythmias, and mortality.
Answers are grounded in this paper and cite their sources.
May lower bleeding and complications in anticoagulated AF; hypothesis-generating and requires RCTs before practice change.
INTRODUCTION: Emerging evidence suggests that sodium‑glucose cotransporter 2 inhibitors (SGLT2is) may be associated with a reduced risk of arrhythmias and related complications. OBJECTIVES: We aimed to evaluate the impact of SGLT2is on atrial fibrillation (AF)-associated adverse outcomes. PATIENTS AND METHODS: All anticoagulated patients with AF diagnosed between January 2014 and December 2020 were identified from a federated electronic medical record database (TriNetX), and followed‑up for 3 years. A 1:1 propensity score matching (PSM) analysis was performed to balance SGLT2i and non‑SGLT2i cohorts. Primary outcomes were bleeding, hospitalizations for AF/atrial flutter (AFl), composite of cardioversion and ablations, and ventricular arrhythmias (VAs) and cardiac arrests. Secondary outcomes included all‑cause mortality, ischemic stroke / transient ischemic attack (TIA), hemorrhagic stroke, incident heart failure (HF), myocardial infarction, and composite of arterial and venous thrombotic events (TEs). Subanalyses were performed on AF‑diabetes and AF‑HF cohorts. RESULTS: As many as 789 758 and 86 249 patients were identified from the non‑SGLT2i and SGLT2i groups, respectively. After PSM, each group had 51 320 patients. The SGLT2i use was associated with a significantly lower risk of bleeding (hazard ratio [HR], 0.669; 95% CI, 0.642-0.697), hospitalization for AF/AFl (HR, 0.826; 95% CI, 0.815-0.837), composite of cardioversion / ablation (HR, 0.652; 95% CI, 0.628-0.678), and VAs and cardiac arrests (HR, 0.779; 95% CI, 0.754-0.805). A lower risk of all‑cause mortality (HR, 0.554; 95% CI, 0.537-0.571), ischemic stroke/TIA (HR, 0.795; 95% CI, 0.768-0.823), hemorrhagic stroke (HR, 0.691; 95% CI, 0.623-0.767), incident HF (HR, 0.856; 95% CI, 0.821-0.893), myocardial infarction (HR, 0.763; 95% CI, 0.736-0.792), and composite of arterial / venous TEs (HR, 0.719; 95% CI, 0.704-0.735) was also observed. CONCLUSIONS: The SGLT2i use was associated with a lower risk of AF‑related complications.
No takes yet. Share an insight, caveat, or question.
Fawzy et al. (2026) conducted an observational in Atrial fibrillation (n=102,640). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. Non-SGLT2i users was evaluated on Bleeding (HR 0.669, 95% CI 0.642-0.697, p=<0.001). SGLT2 inhibitor use was associated with a lower risk of bleeding and other AF-related complications compared to non-use in anticoagulated patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: